Various strategies are being pursued to boost worldwide vaccine coverage.
Academic rigour, journalistic flair
Articles on Intellectual property
Displaying 41 - 60 of 139 articles
The change in the US position signals how clearly the success of every country in fighting the pandemic depends on vaccinating the whole world.
It’s not clear whether the TRIPS agreement is what’s getting in the way of vaccine supply, and waiving intellectual property rights may stifle future innovation.
Increasing skills and the availability of raw materials would be a bigger boost for vaccine production right now.
Pfizer and Moderna are expected to make billions in revenue this year. It’s time all vaccine producers share their IP, data and know-how with the rest of the world.
India and South Africa are pressing the World Trade Organization to waive patent rights to help ramp up vaccine production. There’s a better solution.
Too many patents and too little information about them makes it hard for the system to weed out patents that unfairly block inventors.
To continue the fast-paced collaborative research and innovation we have seen during the pandemic, here are five ways universities can support health research that responds to societal needs.
A waiver may not allow all developing countries to secure medicines and other anti-COVID technologies in a timely way.
Plus new research on why China is closing down coal-fired power stations. Listen to episode 3 of The Conversation Weekly.
Gen Z have been collaboratively writing Ratatouille the Musical on TikTok – but what do the terms of service say about who owns the art?
The story of invention in America typically features larger-than-life caricatures of white men like Thomas Edison while largely ignoring the contributions of women and people of color.
The changes for allow access to orphan works and put beyond doubt the right of academics to quote from copyrighted works.
Innovation means creating and capturing value from new things. And it’s better for the Kiwi economy if investment in that innovation grows local industries and creates jobs.
The TRIPS waiver makes COVID-19 treatments more accessible globally by enabling manufacture and distribution of COVID-19 drugs and medical supplies that would normally be protected by patents.
China represents one of the biggest consumer markets in the world. Can that potential profit offset the problems of investing for multinational corporations? Apparently, yes.
Many countries recruit overseas talent in science and technology, but China’s approach to gaining intellectual property is particularly aggressive.
A unique challenge is emerging in the search for a COVID-19 vaccine: how to balance intellectual property rights with serving the public good.
There’s a risk Australia won’t get access to everything it will need need. It can take are simple stepsto make sure patents don’t get in the way.
Drug companies normally use patents to protect new treatments.
Top contributors
-
Reader in Intellectual Property Law, City, University of London
-
Professor in Intellectual Property and Innovation Law, Queensland University of Technology
-
Associate Professor in Public Health, La Trobe University
-
Professor of Law, University of Sydney
-
Associate Professor, School of Law, University of Canberra
-
Associate Vice President for Entrepreneurship and Innovation, Clemson University
-
Senior Lecturer Above the Bar, University of Canterbury
-
Professor in International Relations / International Political Economy, UNSW Sydney
-
Professor and Distinguished Research Chair, Globalization and Health Equity, L’Université d’Ottawa/University of Ottawa
-
Director, Centre for Transformative Innovation, Swinburne University of Technology
-
ARC Future Fellow; Professor; Director, Intellectual Property Research Institute of Australia, The University of Melbourne
-
Distinguished Professor, Arthur J. Gosnell Professor of Economics, & Interim Head, Department of Sustainability, Rochester Institute of Technology
-
Senior Lecturer in Biochemistry and Cell Biology, University College Cork
-
Professor, University of Gondar
-
Professor of Intellectual Property and Innovation Law; Director Centre for Intellectual Property Policy and Managament (CIPPM), Bournemouth University, Bournemouth University
